Drysdale, M.J. (2013) Fragment-based drug discovery: the shape of things to come. Australian Journal of Chemistry, 66(12), pp. 1544-1549. (doi: 10.1071/CH13255)
Full text not currently available from Enlighten.
Abstract
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of Zelboraf (Vemurafenib) for the treatment of mutant B-RafV600E melanoma, it has become embedded within the pharmaceutical and biotechnology industries. FBDD has delivered clinical development candidates for a broad range of targets including some of the most challenging cases such as β-secretase (BACE1) and protein–protein interactions. But the best is surely still to come.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Drysdale, Dr Martin |
| Authors: | Drysdale, M.J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Australian Journal of Chemistry |
| ISSN: | 0004-9425 |
| ISSN (Online): | 1445-0038 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details